Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection.
Ping-I HsuFeng-Woei TsayJohn Y KaoNan-Jing PengKuo-Wang TsaiTzung-Jiun TsaiChao-Hung KuoSung-Shuo KaoHuay-Min WangYan-Hua ChenChang-Bih ShieDeng-Chyang Wunull nullPublished in: Journal of gastroenterology and hepatology (2020)
Fourteen-day reverse hybrid therapy and 14-day concomitant therapy are equivalent in efficacy for the first-line treatment of H. pylori infection. However, reverse hybrid therapy has fewer adverse events compared with concomitant therapy.